Clinical trial · Observational
Integrated Analysis of Therapy Response and Resistence in Embryonal Tumors and Gliomas
Prospective Collection of Clinical and Imaging Data, Radiotherapy Planning and Biomaterials for Integrated Analysis of Therapy Response and Resistance and Detection of Molecular Targets in Adolescents and Young Adults With CNS Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The treatment of adolescents and young adults (AYA, 15 to 39 years) with malignant intra-axial CNS parenchymal tumors such as IDH-mutated gliomas, medulloblastomas and ependymomas is still not curative in all cases. The tumor biology and clinical needs to diagnose and treat these tumors are comparable across all age groups, so an integrated treatment environment overseen by adult and pediatric neuro-oncology specialists seems promising to leverage synergisms and advance diagnostic and therapeutic development in these tumors. A comprehensive, prospective and integrated biomaterial and imaging-based pipeline for the multi-faceted evaluation of AYAs has not yet been established for AYA patients with brain tumors in Germany. Current diagnostic platforms neglect the integrative processing of data from MRI and FET-PET imaging, radiotherapy plans, tumor tissue, liquid biopsies and clinical data as well as prognostic markers. A prospective AYA pipeline can therefore enable a better understanding of the aforementioned high-risk CNS malignancies and promises clinical advances for AYA patients and the clinical and scientific research landscape.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Embryonal Tumor | Embryonal Neoplasm | CURATED_BROADER | 0.80 |
| Ependymoma | Ependymoma | ONTOLOGY_EXACT | 0.90 |
| Glioma, Malignant | Malignant Glioma | ALIAS | 0.90 |
| Medulloblastoma | Medulloblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Tissue, blood, cerebrospinal-spinal fluid | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Embryonal
- description
- Embryonal tumors, including medulloblastoma and ATRT
- interventionNames
- Diagnostic Test: Tissue, blood, cerebrospinal-spinal fluid
- label
- Glioma, IDH-mutated
- description
- IDH-mutated gliomas, including WHO grades 2, 3 and 4
- interventionNames
- Diagnostic Test: Tissue, blood, cerebrospinal-spinal fluid
Primary outcomes (6)
- measure
- AI processing of MRI fand PET or diagnosis
- timeFrame
- March 2026
- description
- Prediction of diagnosis by artificial intelligence (AI)-assisted processing of magnetic resonance imaging (MRI) and Fluorethyltyrosin-Positron Emission Tomography (FET-PET)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 39 Years
Show eligibility criteria text
Inclusion Criteria: 1. first diagnosis of high-risk CNS tumors including glioma IDHmutated, medulloblastoma, ependymoma and other intra-axial primary brain tumors 2. adolescents and young adults (AYA; 15 to 39 years) 3. Karnofsky status of 60 or higher 4. resection, extended biopsy or stereotactic biopsy with sufficient tissue volume 5. multimodal therapy planned at the discretion of the treating specialist 6. expected survival time of at least 6 months 7. informed consent from the patient or the patient's legal guardian prior to the first study procedure 8. complete material collection expected. Exclusion Criteria: 1. synchronous independent tumor disease other than basal cell carcinoma and carcinoma in situ 2. participation in interventional clinical trial except in standard arms of interventional clinical trials.
References
Publications (0)
Data not yet available